^

Original-Research: Ikonisys SA - von Sphene Capital GmbH

Einstufung von Sphene Capital GmbH zu Ikonisys SA

Unternehmen: Ikonisys SA

ISIN: FR00140048X2

Anlass der Studie: Update Report

Empfehlung: Buy

seit: 31.07.2023

Kursziel: EUR 4,50 (unverändert)

Kursziel auf Sicht von: 36 Monate

Letzte Ratingänderung: -

Analyst: Peter Thilo Hasler, CEFA

Second sale of the high-volume Ikoniscope20max

 

With another sale completed of the Ikonicope20max, the high-end,

high-volume configuration of the Ikoniscope20 for high-throughput

laboratories, we believe Ikonisys is on track to expand its global reach

and to meet our long-term financial targets. We are confirming our Buy

rating for the shares of Ikonisys SA and our price target of EUR 4.50 which

is based on a three-stage DCF entity model (base case scenario). In a Monte

Carlo analysis we used alternative sales and earnings scenarios and

calculated equity values in a range between EUR 45.1m (10% quantile) and

EUR 67.6m (90% quantile), which translate into price targets between EUR

3.50 and EUR 5.30 per share.

Ikonisys announced the second sale and installation of the Ikoniscope20max;

the customer is a specialized urology laboratory in the Midwestern United

States. The Ikoniscope20max is a high-volume configuration of the

Ikoniscope20 specifically designed for high-throughput medium and large

laboratories.

The sale highlights the strong value proposition of the Ikoniscope20 for

laboratories, where we believe Ikonisys has taken a technology leadership

position in laboratory automation, ahead of larger competitors such as

Olympus, Leica, Thermo Fisher, Perkin Elmer, Applied Spectral Imaging,

Bioview, MetaSystems or Zeiss, none of which have achieved such a deep

level of automation as Ikonisys, in our view.

Die vollständige Analyse können Sie hier downloaden:

http://www.more-ir.de/d/27421.pdf

Kontakt für Rückfragen

Peter Thilo Hasler, CEFA

+49 (89) 74443558/ +49 (152) 31764553

peter-thilo.hasler@sphene-capital.de

-übermittelt durch die EQS Group AG.-

Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw.

Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung

oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

°